Aurobindo Pharma Overview

  • Year Founded
  • 1986

Year Founded

  • Status
  • Public

  • Employees
  • 46,455

Employees

  • Stock Symbol
  • AUROPHARMA

Stock Symbol

  • Investments
  • 24

  • Share Price
  • $19.32
  • (As of Thursday Closing)

Aurobindo Pharma General Information

Description

Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are: India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Galaxy, Floors 22-24, Plot No.1, Survey Number 83/1
  • Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District
  • Hyderabad, Telangana 500032
  • India
+91 040
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
NSE
Vertical(s)
Corporate Office
  • Galaxy, Floors 22-24, Plot No.1, Survey Number 83/1
  • Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District
  • Hyderabad, Telangana 500032
  • India
+91 040

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aurobindo Pharma Stock Performance

As of 19-Nov-2026, Aurobindo Pharma’s stock price is $19.32. Its current market cap is $11.1B with 575M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$19.32 $19.22 $12.17 - $19.80 $11.1B 575M 983K $0.74

Aurobindo Pharma Financials Summary

As of 30-Sep-2026, Aurobindo Pharma has a trailing 12-month revenue of $3.96B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 9,754,018 7,852,671 7,971,640 7,558,455
Revenue 3,957,021 3,778,104 3,710,875 3,467,320
EBITDA 881,209 780,380 797,642 707,153
Net Income 430,354 396,628 412,251 383,274
Total Assets 6,429,310 6,200,375 5,820,128 5,404,679
Total Debt 898,455 855,603 965,974 797,140
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aurobindo Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aurobindo Pharma‘s full profile, request access.

Request a free trial

Aurobindo Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturi
Pharmaceuticals
Hyderabad, India
46,455 As of 2026

Mumbai, India
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aurobindo Pharma Competitors (35)

One of Aurobindo Pharma’s 35 competitors is Glenmark Pharmaceuticals, a Corporation company based in Mumbai, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Glenmark Pharmaceuticals Corporation Mumbai, India
Wockhardt Corporation Mumbai, India
Teva Pharmaceutical Industries Corporation Tel Aviv, Israel
GSK Corporation London, United Kingdom
Alkem Laboratories Formerly PE-Backed Mumbai, India
You’re viewing 5 of 35 competitors. Get the full list »

Aurobindo Pharma Patents

Aurobindo Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240358695-A1 Pharmaceutical compositions of rimegepant Pending 25-Apr-2023
US-20240285618-A1 Pharmaceutical compositions of lumateperone Pending 20-Feb-2023
WO-2024171021-A1 A process for the preparation of belumosudil and its Inactive 13-Feb-2023
WO-2024134368-A1 Solid state form of mavacamten Inactive 23-Dec-2022
US-20230390254-A1 Pharmaceutical compositions of ubrogepant and process for preparation thereof Inactive 03-Jun-2022 A61K31/437
To view Aurobindo Pharma’s complete patent history, request access »

Aurobindo Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aurobindo Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Aurobindo Pharma‘s full profile, request access.

Request a free trial

Aurobindo Pharma Investments & Acquisitions (24)

Aurobindo Pharma’s most recent deal was a Corporate with Swarnaaskshu Solar Power. The deal was made on 30-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Swarnaaskshu Solar Power 30-Jun-2026 Corporate Energy Production
Swarnaakshu Solar Power 25-Jun-2026 Corporate Energy Production
Garuda Renewables 09-Feb-2026 Secondary Transaction - Private Energy Production
Khandelwal Laboratories (Non-Oncology prescription formulations business) 01-Jan-2026 Merger/Acquisition Laboratory Services (Healthcare)
GLS Pharma 25-Oct-2024 Secondary Transaction - Private Pharmaceuticals
You’re viewing 5 of 24 investments and acquisitions. Get the full list »

Aurobindo Pharma ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

28.62 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Aurobindo Pharma’s complete esg history, request access »

Aurobindo Pharma Exits (3)

Aurobindo Pharma’s most recent exit was on 07-Nov-2020 from Eugia Pharma Specialities. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Eugia Pharma Specialities 07-Nov-2020 Completed
Natrol 09-Dec-2014 Completed
  • 2 buyers
Eugia Pharma Specialities 17-Apr-2013 Joint Venture Completed
  • 2 buyers
To view Aurobindo Pharma’s complete exits history, request access »

Aurobindo Pharma Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
Tergene Biotech Hyderabad, India 2010
GLS Pharma New Delhi, India 2004
AXIS Clinicals Hyderabad, India 2004
Generis Farmacêutica Amadora, Portugal 2002
Arrow Génériques Lyon, France 2000

Aurobindo Pharma FAQs

  • When was Aurobindo Pharma founded?

    Aurobindo Pharma was founded in 1986.

  • Where is Aurobindo Pharma headquartered?

    Aurobindo Pharma is headquartered in Hyderabad, India.

  • What is the size of Aurobindo Pharma?

    Aurobindo Pharma has 46,455 total employees.

  • What industry is Aurobindo Pharma in?

    Aurobindo Pharma’s primary industry is Pharmaceuticals.

  • Is Aurobindo Pharma a private or public company?

    Aurobindo Pharma is a Public company.

  • What is Aurobindo Pharma’s stock symbol?

    The ticker symbol for Aurobindo Pharma is AUROPHARMA.

  • What is the current stock price of Aurobindo Pharma?

    As of 19-Nov-2026 the stock price of Aurobindo Pharma is $19.32.

  • What is the current market cap of Aurobindo Pharma?

    The current market capitalization of Aurobindo Pharma is $11.1B.

  • What is Aurobindo Pharma’s current revenue?

    The trailing twelve month revenue for Aurobindo Pharma is $3.96B.

  • Who are Aurobindo Pharma’s competitors?

    Glenmark Pharmaceuticals, Wockhardt, Teva Pharmaceutical Industries, GSK, and Alkem Laboratories are some of the 35 competitors of Aurobindo Pharma.

  • What is Aurobindo Pharma’s annual earnings per share (EPS)?

    Aurobindo Pharma’s EPS for 12 months was $0.74.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process